Ipsen S.A. (OTCMKTS:IPSEY - Get Free Report) saw a significant growth in short interest in the month of April. As of April 15th, there was short interest totalling 5,700 shares, a growth of 2,750.0% from the March 31st total of 200 shares. Based on an average daily volume of 9,800 shares, the short-interest ratio is presently 0.6 days. Approximately 0.0% of the company's shares are short sold.
Ipsen Stock Up 4.8 %
Shares of Ipsen stock traded up $1.35 during trading hours on Thursday, reaching $29.55. 703 shares of the company were exchanged, compared to its average volume of 5,800. Ipsen has a 1 year low of $25.11 and a 1 year high of $34.06. The stock's fifty day moving average is $28.51 and its 200 day moving average is $29.37.
Analysts Set New Price Targets
Separately, Deutsche Bank Aktiengesellschaft reissued a "buy" rating on shares of Ipsen in a research note on Wednesday, April 2nd.
Read Our Latest Analysis on IPSEY
Ipsen Company Profile
(
Get Free Report)
Ipsen SA operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.
Read More
Before you consider Ipsen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ipsen wasn't on the list.
While Ipsen currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
